NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Mary B. Daly(Fox Chase Cancer Center), Susan Darlow(National Comprehensive Cancer Network), Matthew B. Yurgelun(Dana-Farber Cancer Institute), Judy E. Garber(Dana-Farber Cancer Institute), Gwen Reiser(University of California San Diego), Patricia Dickson(Washington University in St. Louis), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Christine Laronga(Moffitt Cancer Center), Holly J. Pederson(Cleveland Clinic), Jeffrey N. Weitzel(Cancer Genetics (United States)), Tuya Pal(Vanderbilt University Medical Center), Carolyn S. Menendez(Memorial Sloan Kettering Cancer Center), Kari B. Wisinski(University of Wisconsin Carbone Cancer Center), Michael P. Berry(St. Jude Children's Research Hospital), Kristen M. Shannon(Massachusetts General Hospital), Robert Pilarski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ahmed Elkhanany(University of Alabama at Birmingham), Wendy Kohlmann(University of Utah), Susan M. Domchek(University City Science Center), Allison W. Kurian(Stanford University), Sofía D. Merajver(University of Michigan), Myra Wick(WinnMed), Saundra S. Buys(University of Utah), Mollie L. Hutton(Roswell Park Comprehensive Cancer Center), Kala Visvanathan(Johns Hopkins University), Michael Goggins(Johns Hopkins University), Catherine Klein(University of Utah), Susan Friedman(Facing Our Risk of Cancer Empowered), Mary A. Dwyer(National Comprehensive Cancer Network), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Seema Khan(University of Colorado Cancer Center), Julie Mak(University of Michigan)
Cited by 507
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k